Dr. Park on Considerations of CAR T-Cell Therapy in Relapsed/Refractory ALL

Video

Jae Park, MD, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia.

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia (ALL).

Several factors should be taken into account when considering CAR T-cell therapy for patients with ALL, says Park.

​Patients should be consulted early on regarding their eligibility for CAR T-cell therapy, ​Park explains. Then, optimizing bridging therapy ​is necessary to ensure patients have the best chance of deriving benefit from CAR T-cell therapy. 

Patients are encouraged to reach out regarding any questions they may have as a lot of preparation is involved ​prior to CAR T-cell administration, Park explains. 

In addition, clinical trials can be recommended to eligible patients​ as ALL remains a rare disease, Park concludes. 

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.